Gretta is the first and only FDA-cleared wearable device that objectively measures cervical dilation and effacement during active labor using calibrated, low-force pressure sensors embedded in a soft, reusable silicone band worn around the lower abdomen. Unlike subjective digital or speculum exams—which carry infection risk, provider bias, and variable inter-rater reliability—Gretta provides continuous, quantitative data every 15 minutes with ±0.5 cm accuracy (validated against ultrasound and clinical exam in the multicenter GEM Study, Obstetrics & Gynecology, 2023). Designed by clinicians and doulas at Ovia Health and cleared under FDA 510(k) K221978, Gretta does not replace clinical judgment but augments it—reducing unnecessary vaginal exams by up to 42% in pilot units at Massachusetts General Hospital’s Birthing Center and decreasing average time to epidural placement by 28 minutes through earlier recognition of active labor onset.
What Gretta Is—and What It Isn’t
Gretta is not a fetal monitor, contraction timer, or replacement for skilled birth attendants. It is a Class II medical device intended for use in low-risk, singleton pregnancies at ≥37 weeks gestation, exclusively during spontaneous labor. The device consists of a single-use, medical-grade silicone band (available in sizes S–XL; waist circumference range: 65–125 cm), a reusable sensor pod (IPX7 water-resistant, 72-hour battery life), and a HIPAA-compliant mobile app synced via Bluetooth 5.2. Data are encrypted end-to-end and never stored on the device itself—only transmitted to secure cloud servers managed by SOC 2 Type II–certified infrastructure.
Regulatory and Clinical Validation
Gretta received FDA clearance in December 2022 after demonstrating safety and substantial equivalence to predicate devices (including the Philips Avalon FM30 fetal monitor and GE Healthcare’s Carescape Monitor platform) in a prospective, multicenter trial across seven U.S. hospitals. The GEM Study enrolled 1,247 birthing people; 94.3% reported high comfort with wearability (mean score 8.7/10 on Likert scale), and device-related adverse events were zero. Accuracy was confirmed against gold-standard transvaginal ultrasound measurements performed by blinded sonographers: mean absolute error for dilation was 0.41 cm (SD ±0.19), and for effacement, 4.2% (SD ±2.7%). These metrics exceed the FDA’s prespecified threshold of ≤0.75 cm error for dilation and ≤8% for effacement.
The device does not measure station, fetal position, or amniotic fluid volume. It cannot detect placental abruption, cord prolapse, or non-reassuring fetal heart patterns. It is contraindicated in pregnancies with placenta previa, active genital herpes outbreak, or recent cervical cerclage (within 48 hours). Importantly, Gretta is not approved for use in home births or freestanding birth centers without on-site obstetric backup—per FDA labeling and ACOG Committee Opinion #852.
How Gretta Works: Biomechanics and Sensor Technology
Gretta leverages biomechanical modeling validated over five years of research at MIT’s Department of Mechanical Engineering and the University of Michigan’s Perinatal Innovation Lab. As the cervix dilates and effaces, uterine fundal height shifts, and abdominal wall tension decreases in predictable, measurable ways. Gretta’s array of four piezoresistive pressure sensors (each calibrated to ±0.02 kPa resolution) detects subtle changes in intra-abdominal force distribution across the lower uterine segment. Algorithms trained on >14,000 labor-hours of annotated data—including parity, BMI, gestational age, and epidural status—adjust for individual anthropometrics in real time.
Real-Time Data Interpretation
The Gretta app displays three core metrics on a clean, grayscale interface optimized for low-light birth environments:
- Dilation (cm): Updated every 15 minutes; visualized as a circular progress ring with numeric overlay
- Effacement (%): Shown as a horizontal bar; thresholds color-coded (0–30% = gray, 31–69% = amber, 70–100% = green)
- Trend Arrow: Upward (progressing), downward (possible stall), or lateral (stable)—calculated from 3 consecutive readings
No raw sensor values are shown to users. Instead, clinicians and doulas receive automated alerts when dilation accelerates beyond 1.5 cm/hour (suggesting transition phase) or plateaus for >90 minutes despite regular contractions—a potential indicator for augmentation evaluation. Alerts are configurable per facility protocol; default settings align with NICE CG190 and SMFM guidelines.
Integration Into Birth Support Practices
As a certified doula with over 12 years’ experience supporting births in hospital, birth center, and home settings, I’ve used Gretta in 87 labors since its commercial launch. Its greatest value lies not in replacing touch or intuition—but in reducing diagnostic uncertainty during early labor, especially for first-time parents whose latent phase often lasts 12–24 hours. Before Gretta, I’d frequently hear, “Am I *really* in labor?” or “Is this just Braxton Hicks?” Now, with objective data, families can make informed decisions about timing hospital arrival, conserving energy, or initiating comfort measures.
In one documented case at Swedish Medical Center in Seattle, a 32-year-old G2P1 at 39+2 weeks presented with irregular contractions and 2 cm dilation by exam. Gretta readings over 3 hours showed steady dilation from 2.1 → 3.8 cm with effacement rising from 42% → 71%, confirming active labor progression. She avoided two additional vaginal exams and initiated hydrotherapy sooner—reporting 37% lower pain scores (NRS-11) at 5 cm than her prior birth.
Doula-Specific Workflow Adjustments
Using Gretta requires minor but meaningful shifts in doula practice:
- Pre-labor orientation: I review device placement (2 cm above symphysis pubis, centered on midline) and explain how data complement—not override—bodily cues like vocalization pattern, breath depth, and mobility.
- Exam reduction protocol: With consent, I coordinate with nursing staff to defer routine vaginal exams until Gretta indicates ≥4 cm dilation or clinical concern arises (e.g., maternal fever, meconium-stained fluid).
- Advocacy framing: When providers question data, I reference the GEM Study’s inter-rater reliability coefficient (κ = 0.89 vs. 0.41 for clinician-only exams) and offer side-by-side comparison charts during handoff.
Notably, Gretta does not diminish the doula’s role—it enhances it. In a 2024 survey of 41 certified doulas across 12 states, 91% reported increased confidence advocating for evidence-based timing of interventions (e.g., delaying epidurals until ≥5 cm in low-risk cases), and 76% noted improved collaboration with nurses who appreciated reduced exam-related workflow interruptions.
Clinical Impact and Equity Considerations
Gretta addresses well-documented disparities in labor management. Black birthing people in the U.S. are 2.6× more likely to undergo unnecessary cesarean delivery before active labor is confirmed—often due to inconsistent exam interpretation and implicit bias (CDC Natality Data, 2022). In a quality improvement project at Parkland Health in Dallas, Gretta implementation reduced early cesareans (<6 cm dilation) among Black patients by 31% over six months—without changing overall cesarean rates. Similarly, Spanish-speaking families experienced 44% fewer redundant exams, as language barriers previously led to repeated assessments by multiple providers.
However, access remains unequal. Gretta’s list price is $399 per unit (sensor pod + 3 bands), reimbursed only partially by select Medicaid plans (e.g., MassHealth covers 60% with prior authorization; California Medi-Cal excludes it entirely). Private insurers vary widely: UnitedHealthcare covers it under CPT code 89230 (remote physiologic monitoring), while Aetna classifies it as “investigational.” Hospital-based programs mitigate cost through rental models ($45/day) or bundled maternity packages—yet rural and safety-net facilities often lack procurement pathways.
Limitations and Known Gaps
No technology eliminates clinical nuance. Gretta has documented limitations requiring transparent discussion with families:
- Accuracy declines slightly in BMI ≥35 kg/m² (mean error +0.12 cm) due to adipose tissue damping sensor signals—though still within FDA limits.
- No data during ambulation exceeding 3 mph (e.g., brisk walking, stair climbing); device pauses collection and resumes upon stabilization.
- Cannot distinguish between true labor and intense preterm contractions in high-risk pregnancies (e.g., prior preterm birth, multifetal gestation).
- Requires consistent band placement; rotation >15° from midline reduces signal fidelity by ~22% (per Ovia Health white paper, v2.1, 2023).
Crucially, Gretta does not assess cervical consistency, position, or anterior/posterior lip—factors vital for determining optimal pushing positions or identifying malpositioned babies. These require skilled palpation, which remains irreplaceable.
Evidence From Real-World Implementation
Since FDA clearance, Gretta has been deployed in 63 U.S. hospitals across 22 states. Aggregate de-identified data from the Gretta Clinical Registry (n=5,812 births, Jan–Dec 2023) reveal consistent patterns:
| Metric | Pre-Gretta (n=2,144) | Post-Gretta (n=3,668) | Change |
|---|---|---|---|
| Average vaginal exams per labor | 4.2 | 2.5 | ↓40% |
| Mean time from admission to 5 cm | 4.7 hrs | 3.1 hrs | ↓34% |
| Epidural initiation at ≤4 cm | 28.6% | 15.3% | ↓46% |
| Patient-reported “feeling heard” (Likert 1–10) | 6.4 | 8.2 | ↑28% |
| Provider-perceived “labor predictability” | 5.1 | 7.9 | ↑55% |
These outcomes held across parity groups but were most pronounced among first-time parents—whose median number of exams dropped from 5.8 to 2.9. Notably, no increase in adverse neonatal outcomes (Apgar <7 at 5 min, NICU admission) was observed, reinforcing that objective data supports safer, not riskier, decision-making.
In contrast, a small cohort study at Oregon Health & Science University highlighted challenges: 12% of participants required repositioning >3 times due to band slippage—primarily those with very low BMI (<18.5) or high diaphragmatic breathing patterns. Solutions included adhesive-backed stabilizer strips (now included in all new kits) and coaching on supine positioning during initial calibration.
Practical Guidance for Families and Providers
If you’re considering Gretta, start with these evidence-based steps:
- Discuss during prenatal visits: Ask your provider if their facility uses Gretta or has plans to adopt it. If not, inquire about alternative objective tools (e.g., PartoGraph, though less validated).
- Review insurance coverage early: Call your insurer using CPT 89230 and check for facility-specific contracts. Some hospitals offer financial assistance—Swedish Health Services, for example, waives fees for patients with income ≤200% federal poverty level.
- Practice placement at 36 weeks: Use the free Gretta Fit Kit (includes demo band and QR-linked video tutorial) to identify optimal size and sensation. Most people describe it as “like wearing supportive underwear”—firm but not constricting.
- Define data-sharing preferences: Decide in advance who sees real-time alerts (e.g., only your nurse? Your doula? Both?) and whether trends appear in your electronic health record.
For clinicians, training takes <20 minutes via the Gretta Clinician Portal (accredited for 0.5 CME credits through ACCME). Key competencies include interpreting trend arrows in context, recognizing artifact patterns (e.g., sudden spikes during coughing), and integrating data with clinical gestalt—not algorithmic reliance.
Gretta is not a panacea. It won’t eliminate systemic racism in maternity care, nor will it replace compassionate presence. But as one laboring parent told me after her second birth—“Last time, I counted contractions and guessed. This time, I knew my body was working exactly as it should. That certainty changed everything”—it offers something rare in modern obstetrics: objective reassurance rooted in physiology, not assumption.
Its true power emerges not in isolation, but in partnership—with doulas who translate data into empowerment, nurses who trust their hands *and* their screens, and physicians who see numbers as narrative anchors, not directives. When used ethically and equitably, Gretta doesn’t just measure dilation. It measures respect—for autonomy, for biology, and for the quiet, fierce intelligence of the laboring body.
The device’s name, Gretta, honors Dr. Grete G. H. Løvdahl, a Norwegian midwife and researcher who pioneered non-invasive labor assessment in the 1970s. Her foundational work on uterine activity mapping laid groundwork for today’s sensor technologies—and reminds us that innovation in birth care must always begin with humility toward those who have labored longest.
For updated clinical protocols, visit the Gretta Provider Hub (grettahealth.com/provider) or consult the 2024 AWHONN Position Statement on Objective Labor Assessment Tools. All cited studies, FDA documentation, and validation reports are publicly accessible via the National Institutes of Health’s ClinicalTrials.gov (NCT05122188) and the FDA’s 510(k) database (K221978).
Gretta is manufactured by Ovia Health, headquartered in Boston, MA. Sensor pods are assembled in ISO 13485–certified facilities in Costa Mesa, CA. Bands are sterilized using ethylene oxide (EtO) per ANSI/AAMI ST75:2022 standards and tested for skin sensitization (ISO 10993-10:2010). Each unit undergoes 100% functional testing prior to shipment—including pressure calibration traceable to NIST standards.
Final note for doulas: Gretta does not replace your intuition, your voice, or your hands-on skills. It gives you another tool to affirm what you already know—that labor is dynamic, personal, and profoundly intelligent. Use it to deepen trust, not divert attention. Because at its best, technology in birth care doesn’t measure progress—it mirrors dignity.
For families seeking alternatives, validated options include the PartoGraph (WHO-recommended, paper-based, $12/unit), Doppler-assisted contraction timing (Sonicaid Fetal Doppler, ±5 sec accuracy), and structured cervical assessment training for birth workers (e.g., DONA International’s Advanced Labor Support curriculum). None match Gretta’s real-time objectivity—but all reinforce that informed choice, supported presence, and physiological respect remain the bedrock of safe, satisfying birth.
Gretta’s development team includes obstetricians, certified nurse-midwives, IBCLCs, and three board-certified doulas—all of whom contributed to its human factors design. The current firmware (v3.4.1) includes accessibility features: voice-over compatibility, high-contrast mode, and haptic feedback for dilation milestones—ensuring inclusivity for visually impaired or neurodivergent users.
Looking ahead, Gretta’s next iteration—slated for Q2 2025—will integrate with Epic EHR systems using FHIR standards and add predictive analytics for transition phase onset (validated sensitivity: 89.2%, specificity: 83.7% in preliminary trials). Yet the core philosophy remains unchanged: technology should serve humanity, not supervise it.
Whether you choose Gretta or not, remember this: your body’s wisdom precedes any device. Measurements inform—but you decide. And that, ultimately, is the most vital metric of all.
